Apogee Therapeutics Inc.

NASDAQ: APGE · Real-Time Price · USD
39.49
-0.87 (-2.16%)
At close: May 23, 2025, 3:59 PM
39.48
-0.03%
After-hours: May 23, 2025, 04:20 PM EDT

Company Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.

The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.

The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics Inc.
Apogee Therapeutics Inc. logo
Country United States
IPO Date Jul 14, 2023
Industry Biotechnology
Sector Healthcare
Employees 196
CEO Dr. Michael Thomas Henderson M.D.

Contact Details

Address:
221 Crescent Street
Waltham, Massachusetts
United States
Website https://www.apogeetherapeutics.com

Stock Details

Ticker Symbol APGE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001974640
CUSIP Number 432705309
ISIN Number US4327053090
Employer ID 93-4958665
SIC Code 2836

Key Executives

Name Position
Dr. Michael Thomas Henderson M.D. Chief Executive Officer & Director
Jane Pritchett V. Henderson Chief Financial Officer
Matthew Batters J.D. Chief Legal Officer & Corporate Secretary
Dr. Carl Linden Dambkowski M.D. Chief Medical Officer
Dr. Drew Badger Ph.D. Senior Vice President and Head of Regulatory Affairs & Toxicology
Dr. Rebecca Dabora Ph.D. Chief Development Officer
Emily Cox SVice President & Head of People
Monica Forbes Senior Vice President of Finance
Noel Kurdi Vice President of Investor Relations
Wendy Aspden-Curran Senior Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
May 12, 2025 SCHEDULE 13G/A [Amend] Filing
May 12, 2025 10-Q Quarterly Report
May 12, 2025 8-K Current Report
May 09, 2025 4 Filing
Apr 29, 2025 ARS Filing
Apr 29, 2025 DEFA14A Filing
Apr 29, 2025 DEF 14A Filing
Apr 04, 2025 4 Filing
Mar 11, 2025 8-K Current Report
Mar 07, 2025 4 Filing